Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality (NCT07466953) | Clinical Trial Compass
Not Yet RecruitingPhase 3
Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality
30 participantsStarted 2026-04-01
Plain-language summary
This study aims to evaluate the potential effects of mesenchymal stem cell-derived suspended exosome therapy on facial skin quality using objective imaging analysis. Thirty adult participants will receive intradermal exosome applications in three treatment sessions performed at one-month intervals. Facial skin analysis will be conducted using the VISIA imaging system before each treatment session and six months after the final treatment. The study will examine changes in multiple facial skin characteristics including wrinkles, pigmentation, skin texture, pores, UV spots, red areas, brown spots, and porphyrins to determine whether exosome therapy may improve overall facial skin quality.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* • Adults aged 18 to 65 years
* Individuals presenting facial skin aging signs
* Willingness to undergo three intradermal treatment sessions
* Ability to comply with study visits and follow-up assessments
* Ability to understand the study procedures and provide written informed consent
Exclusion Criteria:
* Pregnancy or breastfeeding
* Active skin infection, inflammatory skin disease, or open wounds in the treatment area
* History of allergic reactions to injectable dermatologic treatments
* Use of systemic or topical retinoids within the past 6 months
* Receipt of facial cosmetic procedures (laser treatment, fillers, botulinum toxin, PRP, or similar treatments) within the past 6 months
* Presence of autoimmune disease or immunosuppressive conditions
* Active malignancy or ongoing cancer treatment
* Participation in another clinical study within the past 3 months
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in composite VISIA absolute score
Timeframe: Baseline to 6 months after the final treatment session